STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the soggy skies hovering over the otherwise peaceful Pharmalot campus.

After all, the Morning Mayor once advised us that “every new day should be unwrapped like a precious gift.” So go ahead, tug on the ribbon while we will brew yet another cuppa stimulation. Our choice today is ginger peach.

For the full experience, we are now hawking replicas —  take a look . Meanwhile, here are a few tidbits to help you along.

We hope your day is productive and peaceful. As always, do keep in touch and do feel free to send along secret dossiers and internal memos.… Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to levels of weight loss approaching the effectiveness seen with bariatric surgery, but there were high rates of side effects and discontinuations, raising questions about how appealing the treatment would be , STAT says.